Seminars in Oncology
Volume 36, Issue 6 , Pages 532-541 , December 2009

Lung Cancer Outcomes in Women

  • Danielle Shafer

      Affiliations

    • Corresponding Author InformationAddress correspondence to Danielle Shafer, DO, Loyola University Medical Center, 2160 S First Ave, Maywood, IL 60153
    • ,
  • Kathy Albain

References 

  1. American Cancer Society. Cancer facts & figures 2008. Atlanta, GA: American Cancer Society; 2008;
  2. Edmonson JH, Lagakos SW, Selawry OS, Perlia CP, Bennett JM, Muggia FM, et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep. 1976;60:925–932
  3. In:  Ries LAG,  Krapcho M,  Stinchcomb DG,  Howlader N,  Horner MJ,  Mariotto A, et al. editor. SEER cancer statistics review, 1975–2005. Bethesda, MD: National Cancer Institute; 2008;http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER website
  4. Kirsh MM, Tashian J, Sloan H. Carcinoma of the lung in women. Ann Thorac Surg. 1982;34:34–39
  5. Bignall JR, Martin M. Survival experience of women with bronchial carcinoma. Lancet. 1972;2:60–62
  6. Harley HR. Cancer of the lung in women. Thorax. 1976;31:254–264
  7. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival (Population-based study of 20 561 cases). Ann Oncol. 2002;13:1087–1093
  8. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest. 2005;127:768–777
  9. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women?. J Clin Oncol. 2007;25:1705–1712
  10. Moore R, Doherty D, Chamberlain R, Khuri F. Sex differences in survival in non-small cell lung cancer patients 1974–1998. Acta Oncol. 2004;43:57–64
  11. Ouellette D, Desbiens G, Emond C, Beauchamp G. Lung cancer in women compared with men: stage, treatment, and survival. Ann Thorac Surg. 1998;66:1140–1143
  12. Henschke CI, Yip R, Miettinen OS. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA. 2006;296:180–184
  13. Cerfolio RJ, Bryant AS, Scott E, Sharma M, Robert F, Spencer SA, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest. 2006;130:1796–1802
  14. Visbal AL, Williams BA, Nichols FC, Marks RS, Jett JR, Aubry MC, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004;78:209–215
  15. Bouchardy C, Fioretta G, De Perrot M, Obradovic M, Spiliopoulos A. Determinants of long term survival after surgery for cancer of the lung: a population-based study. Cancer. 1999;86:2229–2237
  16. Ferguson MK, Wang J, Hoffman PC, Haraf DJ, Olak J, Masters GA, et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg. 2000;69:245–249
  17. Batevik R, Grong K, Segadal L, Stangeland L. The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer. 2005;47:173–181
  18. Martini N, Rusch VW, Bains MS, Kris MG, Downey RJ, Flehinger BJ, et al. Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer. J Thorac Cardiovasc Surg. 1999;117:32–36
  19. Okada M, Nishio W, Sakamoto T, Harada H, Uchino K, Tsubota N. Long-term survival and prognostic factors of five-year survivors with complete resection of non-small cell lung carcinoma. J Thorac Cardiovasc Surg. 2003;126:558–562
  20. Minami H, Yoshimura M, Miyamoto Y, Matsuoka H, Tsubota N. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest. 2000;118:1603–1609
  21. Alexiou C, Onyeaka CV, Beggs D, Akar R, Beggs L, Salama FD, et al. Do women live longer following lung resection for carcinoma?. Eur J Cardiothorac Surg. 2002;21:319–325
  22. Keller SM, Vangel MG, Adak S, Wagner H, Schiller JH, Herskovic A, et al. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer. 2002;37:303–309
  23. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95:1453–1461
  24. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173–182
  25. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360
  26. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–727
  27. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597
  28. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3559
  29. Werner-Wasik M, Scott C, Cox JD, Sause WT, Byhardt RW, Asbell S, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 2000;48:1475–1482
  30. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–1892
  31. Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–386
  32. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26:2450–2456
  33. O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986;4:1604–1614
  34. Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Changes in the natural history of nonsmall cell lung cancer (NSCLC)—comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer. 2006;106:2208–2217
  35. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients (The European Lung Cancer Working Party). J Clin Oncol. 1995;13:1221–1230
  36. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618–1626
  37. Albain KS, Unger J, Gotay CC, Davies AM, Edelman M, Herbst RS, et al. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. [abstract] J Clin Oncol. 2007;25:7549;(Meeting Abstracts)
  38. Mandrekar SJ, Schild SE, Hillman SL, Foster NR, Adjei AA, Marks RS, et al. A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes. [abstract] J Clin Oncol. 2005;23:7193;(Meeting Abstracts)
  39. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  40. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1:441–446
  41. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016–3024
  42. Belani CP, Von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, et al. Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbin-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): analyses by gender. [abstract P-452] Lung Cancer. 2005;49:S235–S236
  43. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  44. Brahmer JR, Gray R, Schiller JH, Perry M, Sandler A, Johnson D. ECOG 4599 phase III trial of carboplatin and paclitaxel {+/−}bevacizumab: subset analysis of survival by gender. [abstract] J Clin Oncol. 2006;24:7036;(Meeting Abstracts)
  45. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol. 2009;27:1227–1234
  46. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:5407–5415
  47. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–2158
  48. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol. 2003;21:2237–2246
  49. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132
  50. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—Molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144
  51. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139
  52. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:4268–4275
  53. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957
  54. Foster N, Mandrekar S, Schild S, Nelson G, Jett J, Adjei A. Age, gender, performance status and stage outperformed stage alone in predicting overall survival (OS) in patients with small cell lung cancer: a pooled analysis of 1,623 patients from the North Central Cancer Treatment Group. [abstract] J Clin Oncol. 2007;25:7723;(Meeting Abstracts)
  55. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986;46:4189–4194
  56. Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, et al. Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol. 1989;7:344–354
  57. Sagman U, Maki E, Evans WK, Warr D, Shepherd FA, Sculier JP, et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. J Clin Oncol. 1991;9:1639–1649
  58. Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer. 1991;63:986–992
  59. Jorgensen LG, Osterlind K, Genolla J, Gomm SA, Hernandez JR, Johnson PW, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer. 1996;74:463–467
  60. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol. 1990;8:1563–1574
  61. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23:850–856
  62. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89:523–533
  63. Danenberg K, Brabender J, Schneider S, Schneider P, Metzger R, Danenberg P. Gender differences in the predictive power of prognostic factors in NSCLC. [abstract] J Clin Oncol. 2004;22:7008;(Meeting Abstracts)
  64. Singer JW, Shaffer S, Baker B, Bernareggi A, Stromatt S, Nienstedt D, et al. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs. 2005;16:243–254
  65. Ross H, Bonomi P, Langer C, O'Brien M, O'Byrne K, Paz-Ares L, et al. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaive pts with advanced NSCLC and poor performance status (PS2). [abstract] J Clin Oncol. 2006;24:7039;(Meeting Abstracts)
  66. Wu CT, Chang YL, Shih JY, Lee YC. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg. 2005;130:979–986
  67. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol. 2009;27:411–417
  68. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000;92:1764–1772
  69. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–991
  70. Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:623–630
  71. O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, et al. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:728–734
  72. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551
  73. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1986;4:702–709

PII: S0093-7754(09)00181-X

doi: 10.1053/j.seminoncol.2009.10.001

Seminars in Oncology
Volume 36, Issue 6 , Pages 532-541 , December 2009

Article Tools